Effect and Efficacy of Onyx™, Zotarolimus-eluting Stent for Coronary Atherosclerosis
Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · May 10, 2017
Trial Information
Current as of May 30, 2025
Unknown status
Keywords
ClinConnect Summary
Secondary endpoints are
1. Stent thrombosis-24 hours(acute), 30 days(subacute), 1 year(late), every 1 year till 3 years(very-late) after index PCI (percutaneous coronary intervention),
2. Target vessel failure
3. Composite rate of cardiac death and any MI, 3 years
4. Composite rate of all death and any MI
5. Composite rate of all death, any MI, and any repeat revascularization
6. Compliance and therapy interruptions with prescribed adjunctive antiplatelet therapy
7. Clinical device and procedural success
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age above 19
- • Patients who received PCI with Resolute Onyx™ stent(s)
- Exclusion Criteria:
- • None
About Seoul National University Hospital
Seoul National University Hospital (SNUH) is a leading medical institution in South Korea, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SNUH integrates cutting-edge scientific inquiry with patient-centered care, facilitating the development of novel therapies and treatment protocols. The hospital boasts a diverse range of specialized departments and a robust infrastructure for conducting clinical studies, ensuring rigorous adherence to ethical standards and regulatory compliance. By fostering collaboration among multidisciplinary teams, SNUH aims to contribute significantly to global medical advancements and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seongnam, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Jinju, , Korea, Republic Of
Suwon, , Korea, Republic Of
Seoul, , Korea, Republic Of
Pusan, , Korea, Republic Of
Seoul, , Korea, Republic Of
Cheonan, , Korea, Republic Of
Chonju, , Korea, Republic Of
Gwangju, , Korea, Republic Of
Jeonju, , Korea, Republic Of
Seoul, , Korea, Republic Of
Gwangju, , Korea, Republic Of
Busan, , Korea, Republic Of
Goyang, , Korea, Republic Of
Patients applied
Trial Officials
Hyo-soo Kim, MD, PhD
Study Chair
Seoul National University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials